Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting the FLUDRO-SHOCK trial to find better treatments for adults with septic shock, a serious condition caused by severe infection. This phase 3 international trial compares two doses of the steroid fludrocortisone 50 mcg and 100 mcg against a placebo, alongside the usual hydrocortisone treatment. The study also investigates how a persons gene-based immune response may influence treatment effects. Up to 2,200 critically ill patients in intensive care units across multiple countries are expected to participate. Participants will receive either 50 mcg or 100 mcg of fludrocortisone acetate daily, or a matching placebo tablet, given orally or through a gastric tube for 7 days or until discharge from intensive care, whichever comes first. The study uses a randomized, double-blind design to fairly compare these treatments. Researchers will closely monitor patients during this treatment period. Throughout the study, participants survival, organ support needs, and quality of life will be tracked for up to one year after enrollment. Assessments include the number of days alive without organ support, mortality at multiple time points, new kidney therapy needs, mechanical ventilation days, hospital readmissions, new infections, and functional and health-related quality of life questionnaires. This comprehensive monitoring aims to help identify the most effective and personalized steroid treatment approach for septic shock.
Actively Recruiting
Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.